Female Hormone Panel: Understanding Your Blood Test Series

1. Overview: What this panel reveals and why it is important

The female hormone panel is not a static set of numbers—it is a dynamic interrogation of the hypothalamic‑pituitary‑ovarian (HPO) axis. Unlike a fixed organ function test, the HPO axis is in constant flux, varying across the menstrual cycle, the lifespan, and in response to stress, nutrition, and energy availability. A single hormone value drawn on a random day is often meaningless; the power lies in timing, cyclicity, and the relationship between hormones.

The panel answers four distinct questions depending on the clinical context:

· Ovulatory function: Is ovulation occurring regularly? (Progesterone, luteal phase)

· Ovarian reserve: How many oocytes remain? (AMH, FSH, inhibin B)

· Androgen excess: Is there biochemical evidence of PCOS or another hyperandrogenic disorder? (Testosterone, free testosterone, DHEA-S, androstenedione)

· Menopausal status: Has ovarian senescence occurred? (FSH, estradiol)

· Pituitary integrity: Is the drive to the ovary appropriate? (FSH, LH, prolactin)

No single hormone is diagnostic in isolation. An elevated FSH may indicate menopause—or primary ovarian insufficiency—or a lab error. A low AMH may indicate diminished reserve—or oral contraceptive use—or natural age-appropriate decline. A mildly elevated prolactin may be stress-induced, medication-induced, or a pituitary microadenoma. The pattern across the axis, correlated with cycle day and clinical phenotype, is what guides the clinician.

Thus, the female hormone panel is a conversation between the hypothalamus, the pituitary, the ovary, and the calendar. Listen to the cycle day. Interpret the ratios. Treat the axis—not the individual number.

---

2. What does it measure

A comprehensive female hormone panel includes the following components. Reference ranges are highly cycle-day dependent and laboratory-specific; values below are approximate for a normally menstruating adult.

A. Gonadotropins (Pituitary drive)

· Follicle-stimulating hormone (FSH):

· Early follicular (day 2–4): 3–10 mIU/mL

· Midcycle peak: 5–20 mIU/mL

· Postmenopausal: >25–30 mIU/mL

· Clinical significance: Stimulates follicular growth; elevated in primary ovarian insufficiency, menopause, poor ovarian reserve; suppressed by oral contraceptives, GnRH agonists.

· Luteinising hormone (LH):

· Early follicular: 2–8 mIU/mL

· Midcycle surge: 20–100 mIU/mL

· Postmenopausal: >25–30 mIU/mL

· Clinical significance: Triggers ovulation; LH:FSH ratio >2 in early follicular phase suggests PCOS; suppressed by GnRH analogues, high-dose oestrogen.

B. Ovarian hormones (End-organ output)

· Estradiol (E2):

· Early follicular: 20–80 pg/mL

· Preovulatory peak: 200–600 pg/mL

· Luteal phase: 60–200 pg/mL

· Postmenopausal: <20 pg/mL

· Clinical significance: Most potent oestrogen; reflects follicular activity, maturation, and ovarian synthetic capacity. Very high levels in ovarian hyperstimulation, oestrogen-secreting tumours.

· Progesterone (P4):

· Follicular phase: <1.0 ng/mL

· Mid-luteal (day 21–23): >5–10 ng/mL (confirms ovulation)

· Pregnancy: rises exponentially

· Clinical significance: Ovulation confirmation; luteal phase adequacy; corpus luteum function. Low luteal progesterone suggests anovulation or inadequate luteal phase.

C. Androgens (Ovarian and adrenal)

· Total testosterone:

· Female reference: 15–70 ng/dL (0.5–2.4 nmol/L)

· Clinical significance: Elevated in PCOS, ovarian or adrenal tumours, congenital adrenal hyperplasia, exogenous androgen use.

· Free testosterone (calculated or equilibrium dialysis):

· 0.3–1.9 pg/mL (varies by assay)

· Clinical significance: Biologically active fraction; superior to total testosterone for detecting mild hyperandrogenism (PCOS, idiopathic hirsutism). SHBG influences free fraction.

· Sex hormone-binding globulin (SHBG):

· 30–100 nmol/L (varies widely)

· Clinical significance: Binds testosterone and oestradiol; low in insulin resistance, obesity, PCOS, hypothyroidism; high in pregnancy, oral contraceptive use, hyperthyroidism, liver disease.

· Dehydroepiandrosterone sulfate (DHEA-S):

· 35–430 mcg/dL (age-dependent)

· Clinical significance: Adrenal androgen; elevated in adrenal hyperandrogenism (PCOS subset, congenital adrenal hyperplasia, adrenal tumours). Does not exhibit circadian variation; stable.

· Androstenedione:

· 0.7–3.1 ng/mL

· Clinical significance: Ovarian and adrenal origin; precursor to testosterone; elevated in PCOS, congenital adrenal hyperplasia, adrenal tumours.

D. Ovarian reserve markers (Quantitative, not qualitative)

· Anti-Müllerian hormone (AMH):

· Age-dependent; approximate: 1–4 ng/mL (reproductive age)

· Clinical significance: Produced by preantral and small antral follicles; reflects ovarian follicular pool. Not cycle-dependent; can be drawn any day. Low AMH indicates diminished ovarian reserve; very high AMH (>4–5 ng/mL) suggests PCOS (excess small follicles).

· Inhibin B:

· Early follicular: 10–100 pg/mL

· Clinical significance: Produced by developing follicles; declines with age; low in diminished ovarian reserve, menopause.

E. Prolactin (Lactotroph hormone)

· Prolactin:

· Non-pregnant: 5–25 ng/mL

· Clinical significance: Elevated by stress, sleep, nipple stimulation, coitus, medications (antipsychotics, metoclopramide, SSRIs), hypothyroidism, renal failure, pituitary adenoma. Mild elevation (25–50) common, often non-pathological.

F. Additional/ancillary tests (context-dependent)

· 17-hydroxyprogesterone (17-OHP):

· Follicular phase: <200 ng/dL

· Clinical significance: Screen for non-classic congenital adrenal hyperplasia (21-hydroxylase deficiency) in hyperandrogenic women; elevated >300 ng/dL prompts ACTH stimulation test.

· Thyroid function tests (TSH, free T4):

· Clinical significance: Hypothyroidism causes ovulatory dysfunction, hyperprolactinaemia, menstrual irregularity; routine co-assessment in reproductive endocrinology.

---

3. Other factors connected to this panel

Preanalytical and biological variables:

· Cycle day timing – the single most critical variable:

· FSH, LH, estradiol: Must be drawn in early follicular phase (day 2–4) for accurate interpretation of ovarian reserve and baseline status. Midcycle or luteal values are uninterpretable for this purpose.

· Progesterone: Must be drawn 7 days before expected menses (day 21 of 28-day cycle) to confirm ovulation. Random progesterone is meaningless.

· Androgens: Can be drawn any cycle day, but early follicular preferred (minimises follicular variation). Suppressed by oral contraceptives.

· AMH: No cycle dependence; any day.

· Fasting status: Not required for most hormones, but insulin and glucose may accompany PCOS workup (fasting required). Prolactin is elevated by recent meals.

· Time of day:

· Prolactin: Draw 2–4 hours after awakening; peaks during sleep, declines by mid-morning. Avoid recent breast examination, nipple stimulation, stress.

· Testosterone: Modest morning peak; draw before 10 AM if possible.

· DHEA-S: Stable throughout day.

· Recent hormone use:

· Oral contraceptives, hormonal IUDs, progestin implants, rings, patches: Suppress FSH, LH, estradiol, ovarian androgens; SHBG rises (oral route). Accurate baseline assessment requires discontinuation (typically 2–3 months) unless assessing suppressive therapy.

· GnRH agonists/antagonists: Profoundly suppress gonadotropins and ovarian hormones.

· Pregnancy: hCG suppresses FSH/LH; prolactin rises; SHBG rises; all androgen interpretation confounded. Do not perform routine female hormone panel in known pregnancy.

· Lactation: Prolactin elevated; gonadotropins suppressed; amenorrhoea physiological.

· Acute illness / stress: Prolactin elevated; gonadotropins may be suppressed (functional hypothalamic suppression). Defer testing.

· Exercise: High-intensity endurance training suppresses GnRH pulsatility → functional hypothalamic amenorrhoea (low FSH, LH, estradiol; normal/low prolactin).

· Weight / body composition:

· Obesity: Low SHBG → elevated free testosterone despite normal total testosterone; oestrogen excess (aromatisation in adipose) → chronic anovulation; AMH may be slightly higher in PCOS, lower in obesity without PCOS.

· Underweight / rapid weight loss: Hypothalamic suppression; low LH, low estradiol, low/normal FSH.

· Age:

· Neonatal: Mini-puberty (FSH, LH, estradiol transiently elevated).

· Puberty: Progressive rise in gonadotropins and oestradiol; anovulatory cycles common in first 2–3 years.

· Reproductive age: Cyclical pattern as described.

· Perimenopause: Rising FSH (normal estradiol initially), later declining estradiol, erratic cycles, elevated AMH variability.

· Postmenopause: FSH >25–30, LH elevated, estradiol <20, AMH undetectable, androgens decline gradually (ovarian stroma continues some production).

Medications affecting panel components:

Elevate prolactin:

· Antipsychotics (risperidone > haloperidol, olanzapine)

· Antiemetics (metoclopramide, domperidone)

· Antidepressants (SSRIs, particularly fluoxetine; less with sertraline, citalopram)

· Verapamil, methyldopa, opiates

· Oestrogens (oral)

Suppress gonadotropins:

· Oral contraceptives, hormonal IUDs, implants, rings

· GnRH agonists (leuprolide, goserelin) – initial flare, then suppression

· GnRH antagonists (cetrorelix, ganirelix)

· High-dose progestins, danazol

· Opiates (chronic)

Affect androgens / SHBG:

· Increase SHBG: Oral oestrogens, pregnancy, hyperthyroidism, anticonvulsants (phenytoin, carbamazepine)

· Decrease SHBG: Androgens, anabolic steroids, glucocorticoids, insulin resistance, obesity, hypothyroidism

· Increase testosterone: Anabolic steroids, danazol, some progestins (norethisterone)

· Decrease testosterone: Oral contraceptives, GnRH agonists, spironolactone, finasteride (5-alpha-reductase inhibitors)

Affect AMH:

· Suppress AMH: GnRH agonists, chemotherapy, ovarian irradiation; oral contraceptives cause modest, reversible decline (20–30%)

· No effect: Metformin, statins, most lifestyle interventions

Interfere with laboratory assays:

· Biotin: High-dose biotin (hair, skin, nail supplements) causes falsely low FSH, LH, estradiol, testosterone and falsely high progesterone on streptavidin-biotin immunoassays. Must discontinue ≥48 hours (longer if mega-doses) before testing.

· Heterophile antibodies: May cause falsely elevated or suppressed values; suspect if result discordant with clinical picture.

Physiological and demographic factors:

· Ethnicity: PCOS prevalence varies; African American and Hispanic women have higher prevalence of metabolic phenotype; Asian women may have lower BMI but similar hyperandrogenism. AMH levels are higher in Black women compared to Caucasian women of same age.

· Smoking: Anti-oestrogenic effect; earlier menopause, lower AMH. Not recommended.

· Alcohol: Suppresses gonadotropins, directly toxic to ovarian follicles; no safe threshold. Complete abstinence advised.

· Caffeine: No consistent direct effect on HPO axis; may exacerbate anxiety, insomnia, fibrocystic breast changes. Not recommended.

---

4. Disorders related to abnormal values: Pattern recognition

The female hormone panel is best interpreted by axis-based pattern recognition, anchored to cycle day and clinical context. Below are the dominant endocrine syndromes.

a. Hypothalamic-pituitary suppression pattern (Functional hypothalamic amenorrhoea)

Laboratory profile:

· FSH: Low or low-normal (typically <5 mIU/mL)

· LH: Low (often <3 mIU/mL; may be equal to or lower than FSH)

· Estradiol: Low (<30–40 pg/mL)

· Prolactin: Normal

· AMH: Normal for age (ovarian reserve intact)

· Progesterone: Anovulatory (<1.0)

Differential diagnosis:

· Functional hypothalamic amenorrhoea: Energy deficit (low caloric intake, excessive exercise, stress, weight loss). Most common cause of amenorrhoea in young, non-obese women.

· Kallmann syndrome / isolated GnRH deficiency: Anosmia (Kallmann), pubertal delay; genetic.

· Pituitary lesion: Craniopharyngioma, non-functioning adenoma (mass effect compressing gonadotrophs); may also have low prolactin, other pituitary deficits.

· Infiltrative: Sarcoidosis, haemochromatosis, lymphocytic hypophysitis.

Outlier scenarios:

· Low FSH/LH, low estradiol, normal prolactin, stress/exercise history: Functional hypothalamic amenorrhoea; do not image unless other pituitary deficits or persistent after refeeding.

· Low FSH/LH, low estradiol, high prolactin: Consider pituitary stalk effect (prolactinoma compressing stalk) or mixed tumour; MRI pituitary.

---

b. Primary ovarian insufficiency / Menopause pattern (Hypergonadotropic hypogonadism)

Laboratory profile:

· FSH: Elevated (>25–30 mIU/mL; often >40)

· LH: Elevated (parallels FSH)

· Estradiol: Low (<20 pg/mL)

· AMH: Low or undetectable

· Inhibin B: Low

· Age <40 years: Primary ovarian insufficiency (POI)

· Age >45–50: Menopause (physiological)

Differential diagnosis:

· Physiological menopause: Age-appropriate ovarian senescence.

· Primary ovarian insufficiency (POI): Autoimmune (most common; associated with thyroid/adrenal autoimmunity), genetic (Turner mosaic, FMR1 premutation), post-chemotherapy/radiation, post-oophorectomy, idiopathic.

· Resistant ovary syndrome (Savage syndrome): FSH elevated, AMH detectable, follicles present but FSH-resistant; rare.

Outlier scenarios:

· FSH elevated, estradiol normal, woman <40: Early POI/perimenopause transition; AMH low. Fertility window limited; do not dismiss.

· FSH elevated, estradiol normal, regular cycles: Incipient ovarian ageing; may have reduced fertility but not yet POI.

· FSH elevated, LH low/normal: Consider pituitary resistance, FSH-secreting pituitary adenoma (rare; macroprolactinoma can cause elevated FSH).

---

c. Polycystic ovary syndrome pattern (Hyperandrogenic anovulation)

Laboratory profile (Rotterdam criteria – requires 2 of 3):

1. Hyperandrogenism: Elevated total or free testosterone, or clinical hirsutism/acne.

2. Oligo-anovulation: Irregular cycles, low luteal progesterone.

3. Polycystic ovarian morphology on ultrasound (not hormonal).

Typical biochemical findings:

· LH:FSH ratio >2 in early follicular phase (not required for diagnosis; present in ~50%)

· Testosterone: Mildly to moderately elevated (total 50–90 ng/dL; free elevated)

· SHBG: Low (insulin resistance suppresses hepatic production)

· AMH: Elevated (>4–5 ng/mL, often much higher) – reflects excess small antral follicles

· Estradiol: Low-normal follicular phase (arrested follicular growth)

· Progesterone: Anovulatory (<1.0)

· 17-OHP: Normal (<200 ng/dL) – excludes non-classic CAH

Differential diagnosis:

· PCOS (primary): Diagnosis of exclusion after ruling out other hyperandrogenic disorders.

· Non-classic congenital adrenal hyperplasia (NCAH): 21-hydroxylase deficiency; elevated 17-OHP (>200 ng/dL) and ACTH-stimulated >1000 ng/dL.

· Androgen-secreting tumour: Rapid onset, very high testosterone (>150–200 ng/dL), DHEA-S >700 mcg/dL, virilisation.

· Cushing syndrome: Hypercortisolism, moon facies, striae, central obesity; confirm with dexamethasone suppression, urinary cortisol.

· Idiopathic hirsutism: Normal testosterone, normal menses, normal ultrasound; diagnosis of exclusion.

· Hyperprolactinaemia: May cause mild androgen elevation, anovulation; prolactin elevated.

Outlier scenarios:

· PCOS with normal androgens: Clinical hyperandrogenism (hirsutism) alone sufficient; some women have normal biochemical profile but clear clinical phenotype.

· PCOS with elevated DHEA-S: Adrenal component; 20–30% of PCOS; treat similarly.

· Very high AMH (>10 ng/mL) with normal menses: May represent PCOS variant or benign AMH elevation; not a disease if ovulatory and euandrogenic.

---

d. Luteal phase defect / Inadequate luteal progesterone

Laboratory profile:

· Mid-luteal progesterone <5–10 ng/mL (threshold varies; <5 suggests anovulation; 5–10 suggests inadequate luteal support)

· Follicular phase hormones normal

· Cycle length may be short (≤24 days) or normal

Differential diagnosis:

· Physiological: Occasional anovulatory cycle in perimenarche, perimenopause, or even normal reproductive life.

· Poor follicular development: Elevated FSH, low estradiol → inadequate granulosa cell mass → insufficient corpus luteum.

· Hyperprolactinaemia: Suppresses GnRH, impairs luteal function.

· Thyroid dysfunction: Hypothyroidism impairs luteal progesterone secretion.

· Endometriosis: Associated with luteal phase dysfunction.

· Obesity / insulin resistance: May impair folliculogenesis and luteal function.

Outlier scenarios:

· Single low progesterone: May be mistimed draw; repeat next cycle.

· Persistent low progesterone with normal FSH, normal prolactin, normal thyroid: Idiopathic; treat with progesterone supplementation if infertility or recurrent pregnancy loss.

---

e. Hyperprolactinaemia pattern

Laboratory profile:

· Prolactin >25 ng/mL (mild: 25–50; moderate: 50–100; severe: >100–200)

· FSH/LH: Low or normal (suppressed by prolactin)

· Estradiol: Low or normal (hypogonadism if chronic)

· May have galactorrhoea, oligo-amenorrhoea

Differential diagnosis:

· Physiological: Stress, sleep, coitus, nipple stimulation, pregnancy, lactation.

· Medication-induced: Antipsychotics, antiemetics, SSRIs, verapamil, methyldopa, opiates.

· Hypothyroidism: TRH stimulates prolactin; check TSH.

· Renal failure: Decreased clearance.

· Pituitary adenoma (prolactinoma): Microadenoma (<10 mm) or macroadenoma (≥10 mm). Macroadenoma may cause mass effects (headache, visual field defect).

· Macroprolactinaemia: Prolactin bound to immunoglobulin; biologically inactive, causes falsely elevated assay but no symptoms. Check with PEG precipitation.

Outlier scenarios:

· Prolactin >500 ng/mL: Macroprolactinoma until proven otherwise.

· Mild prolactin elevation (25–50), normal TSH, no drugs, no galactorrhoea: Idiopathic; repeat without stress, early morning.

· Prolactin elevated, TSH elevated: Treat hypothyroidism; prolactin normalises.

---

f. Diminished ovarian reserve pattern (Low AMH / High FSH)

Laboratory profile:

· AMH: Low for age (age-specific nomograms; approximate: <1.0 ng/mL age 30–35, <0.5 age 40+)

· FSH: Early follicular >10 mIU/mL (trend, not single value, more reliable)

· Inhibin B: Low

· Estradiol: Normal or low

· Regular cycles may persist despite low reserve.

Differential diagnosis:

· Physiological ageing: Decline begins ~age 32; accelerates after 37.

· Premature ovarian ageing: Age-appropriate but low reserve; no diagnostic consensus.

· Post-chemotherapy / pelvic radiation: Iatrogenic depletion.

· Endometrioma surgery: Ovarian tissue loss.

· Genetic: FMR1 premutation (check in family history of POI/neurodevelopmental disorders).

Outlier scenarios:

· Low AMH, regular cycles, age <35: Counselling; does not predict inability to conceive, but shorter window.

· Undetectable AMH, regular cycles: Consider assay variability; repeat with different platform; possible but rare.

· Low AMH, elevated FSH, age <40: POI imminent; refer fertility preservation if appropriate.

---

g. Androgen deficiency pattern (Female hypoandrogenism)

Laboratory profile:

· Total or free testosterone: Below reference range

· DHEA-S: Low

· SHBG: Variable

· FSH/LH/estradiol: Variable (depends on menopausal status, hormone therapy)

Differential diagnosis:

· Physiological: Age-related decline; postmenopausal ovaries produce less testosterone.

· Hypopituitarism: Secondary adrenal and ovarian failure.

· Adrenal insufficiency: Primary or secondary; low DHEA-S.

· Oral contraceptive use: Suppresses ovarian androgen production, raises SHBG → marked reduction in free testosterone.

· Oophorectomy: Bilateral salpingo-oophorectomy reduces circulating testosterone by ~50%.

Clinical significance:

· Controversial. Some women report low libido, fatigue, depressed mood. Female sexual dysfunction is multifactorial; androgen replacement not routinely recommended. Testosterone therapy in women is not FDA-approved for hypoactive sexual desire disorder; used off-label with significant safety concerns (hirsutism, acne, virilisation, long-term cardiovascular unknown).

Outlier scenario:

· Very low testosterone, undetectable DHEA-S, young woman with oligomenorrhoea: Evaluate for hypopituitarism (check cortisol, IGF-1, TSH, prolactin, MRI pituitary).

---

5. Best way to address aberrant levels: A holistic approach

Critical principle: The female hormone panel is a measure of axis function, not a diagnostic label. Do not treat an isolated low AMH with supplements; do not treat an elevated LH:FSH ratio with ovulation induction drugs without establishing ovulatory status; do not treat mildly elevated prolactin with cabergoline without excluding drugs, hypothyroidism, stress. Empiric hormone therapy without diagnostic clarity may obscure serious pathology (prolactinoma, androgen-secreting tumour, thyroid disease).

a. Diagnostic algorithm, not therapeutic trial

Step 1: Confirm the abnormality

· Repeat any value that is discordant with clinical picture, drawn on incorrect cycle day, or drawn during acute illness/stress.

· Check biotin use – discontinue ≥48 hours.

· Check TSH with every prolactin elevation.

· Check 17-OHP with every hyperandrogenemia workup.

Step 2: Anchor interpretation to cycle day and context

· Is the patient menstruating regularly? If yes, day 2–4 FSH/LH/E2; day 21 progesterone.

· Is the patient amenorrhoeic or oligo-ovulatory? Random draw acceptable; FSH/LH/E2/PRL/TSH/androgens/AMH.

· Is the patient on hormonal contraception? Stop 2–3 months before assessment unless assessing suppression.

Step 3: Identify the dominant pattern (see Section 4)

· Hypothalamic suppression (low FSH/LH/E2)

· Primary ovarian insufficiency (high FSH, low E2, low AMH)

· PCOS (hyperandrogenism + oligo-ovulation + elevated AMH)

· Hyperprolactinaemia

· Diminished ovarian reserve (low AMH, high FSH)

· Luteal phase defect

Step 4: Treat the underlying cause

Hypothalamic amenorrhoea / Functional:

· Increase caloric intake, reduce exercise intensity, address stress. Cognitive behavioural therapy effective.

· No pharmacotherapy unless infertility desired – then pulsatile GnRH or gonadotropins.

· Oestrogen replacement for bone health if persistent hypoestrogenism >6–12 months (transdermal oestradiol + cyclic progesterone).

Primary ovarian insufficiency:

· Hormone therapy until average age of menopause (50–51) – transdermal oestradiol + progesterone (or oestrogen + IUD if bleeding desired). Protects bone, cardiovascular, cognitive health.

· Screening for autoimmune comorbidities: Thyroid (TSH, TPOAb), adrenal (21-hydroxylase antibodies), pernicious anaemia, type 1 diabetes.

· Fertility: Donor oocyte, adoption; 5–10% chance of spontaneous conception, unpredictable.

PCOS (phenotype-driven treatment):

· Hyperandrogenism / hirsutism:

· Combined oral contraceptive (first-line) – suppresses ovarian androgen production, raises SHBG.

· Anti-androgens: Spironolactone, cyproterone acetate (only with effective contraception; teratogenic).

· Topical eflornithine for facial hirsutism.

· Oligo-ovulation / infertility:

· Letrozole (first-line) – superior to clomiphene for live birth in PCOS.

· Metformin: Only if glucose intolerance or failed letrozole; not first-line for ovulation induction.

· Metabolic: Lifestyle intervention (diet, exercise, weight loss) – 5% weight loss restores ovulation in many. Metformin, GLP-1 agonists if obesity/diabetes.

· AMH elevation: No treatment needed; correlates with follicular excess, not a disease.

Hyperprolactinaemia:

· Drug-induced: Discontinue or substitute causative agent.

· Hypothyroidism: Levothyroxine.

· Microprolactinoma: Dopamine agonists (cabergoline first-line, better tolerated than bromocriptine). Normalises prolactin, restores gonadal function, shrinks tumour.

· Macroprolactinoma: Urgent ophthalmology, endocrine referral; dopamine agonists.

· Macroprolactinaemia: No treatment; reassurance.

Diminished ovarian reserve:

· No proven treatment to increase AMH or improve oocyte quality. Coenzyme Q10, DHEA, melatonin show weak, inconsistent evidence. Do not market or promise fertility enhancement.

· Fertility: If pursuing pregnancy, refer early for IVF/ICSI; consider preimplantation genetic testing if advanced maternal age.

Luteal phase defect:

· Progesterone supplementation (vaginal, oral, or intramuscular) in luteal phase of stimulated cycles (IVF, ovulation induction). Role in natural conception controversial.

· Treat underlying cause: Hypothyroidism, hyperprolactinaemia, weight extremes.

---

b. Role of supplements and holistic medicine – supportive only

Ovulatory function and PCOS:

· Inositol (myo-inositol and D-chiro-inositol): 2–4 g/day myo-inositol + 50–100 mg D-chiro-inositol (40:1 ratio). Improves insulin sensitivity, ovulation rates, and modestly lowers androgens in PCOS. Adjunctive; not a substitute for lifestyle or pharmacotherapy.

· N-acetylcysteine (NAC): 600–1200 mg/day; modest improvement in ovulation and metabolic parameters in PCOS; inferior to metformin.

· Berberine: 500 mg three times daily; lowers glucose, androgens; similar efficacy to metformin in some trials; gastrointestinal side effects; drug interactions.

· Vitamin D3: Deficiency associated with PCOS severity, insulin resistance, anovulation; supplement to maintain optimal levels.

· Zinc, chromium, magnesium: Correct deficiencies; insufficient evidence for routine supplementation in absence of deficiency.

Ovarian reserve / fertility (adjunctive, weak evidence):

· Coenzyme Q10 (ubiquinol): 200–600 mg/day; antioxidant; may improve ovarian response in poor responders; inconsistent trial data.

· Dehydroepiandrosterone (DHEA): 25–75 mg/day; controversial; some studies show improved IVF outcomes in diminished ovarian reserve; others negative. Not FDA-approved; long-term safety unknown. Not recommended for routine use.

· Melatonin: 2–3 mg at bedtime; antioxidant in follicular fluid; modest improvement in oocyte quality in some studies.

· Alpha-lipoic acid: Antioxidant; insufficient evidence.

Hyperprolactinaemia:

· Vitex agnus-castus (chasteberry): Dopaminergic activity; may reduce mild prolactin elevation, improve luteal phase symptoms. Weak, inconsistent evidence; interacts with dopamine agonists. Not recommended with prolactinoma or concurrent antipsychotics.

Herbs and Phytochemicals from Indian subcontinent (adjunctive, not primary):

· Shatavari (Asparagus racemosus): Traditional use for female reproductive health; no robust evidence for hormonal disorders. Theoretical phytoestrogenic effects; avoid in hormone-sensitive conditions.

· Ashwagandha (Withania somnifera): Adaptogen; may reduce stress, cortisol; small study suggests improved FSH, LH, estradiol in stressed women. Not for hyperandrogenism or PCOS.

· Guduchi (Tinospora cordifolia): Immunomodulatory; no direct evidence for female hormone disorders.

· Never use as substitute for definitive therapy (hormone replacement, dopamine agonists, ovulation induction).

Critical warnings:

· Do not use black cohosh, red clover, or soy isoflavones for menopausal symptoms in women with breast cancer or high risk – phytoestrogens may stimulate oestrogen-sensitive tissue. Evidence of benefit is mixed; safety in breast cancer survivors not established.

· Do not use DHEA without measuring baseline DHEA-S and testosterone – risk of iatrogenic hyperandrogenism, acne, hirsutism, virilisation.

· Avoid all products containing undisclosed oestrogen, progesterone, testosterone, or corticosteroids (adulterated "herbal" hormone supplements).

· Do not supplement iodine for ovarian cysts or fibroids – no benefit, risk of thyroid dysfunction.

---

c. Dietary and lifestyle approach (plant‑forward, ecologically sustainable)

Core principles for female endocrine health:

· Adequate energy availability: The HPO axis is exquisitely sensitive to caloric deficit. Undereating and overexercise suppress GnRH. Maintain energy balance; do not restrict calories below 1800–2000 kcal/day in active reproductive-age women without medical indication.

· Healthy body weight: Both underweight and obesity impair ovulation, increase miscarriage risk, and alter hormone profiles. 5–10% weight loss in overweight/obese PCOS restores ovulation in 30–50%.

· Mediterranean dietary pattern: Highest evidence for PCOS, fertility, and general endocrine health. Emphasises vegetables, fruits, legumes, whole grains, nuts, seeds, extra‑virgin olive oil; limits red meat, processed foods, refined carbohydrates.

· Low glycaemic load / high fibre: Improves insulin sensitivity, lowers androgens in PCOS. Replace refined grains with whole grains; eliminate sugary beverages.

· Adequate protein: Plant-based sources preferred; legumes, tofu, tempeh, quinoa, nuts, seeds. No requirement for animal protein.

· Healthy fats: Emphasise monounsaturated and omega-3 fatty acids (olive oil, avocado, flaxseed, chia, walnuts, algae oil). Limit saturated and trans fats.

· Eliminate industrial trans fats: Associated with anovulation, infertility, endometriosis.

· Alcohol: complete abstinence. Alcohol suppresses gonadotropins, directly toxic to ovarian follicles, increases oestrogen metabolism dysregulation, and has addiction potential. No safe threshold.

· Caffeine: Not recommended. Some studies associate high intake with delayed conception, increased miscarriage risk; exacerbates anxiety, fibrocystic breast changes, insomnia.

· Tobacco: Anti-oestrogenic; accelerates ovarian ageing, lowers AMH, advances menopause. Complete cessation mandatory.

· Regular physical activity: Moderate exercise (150 minutes/week) improves insulin sensitivity, metabolic health, mood. Excessive high-intensity endurance training without adequate nutrition causes hypothalamic suppression.

Plant-based protein sources (ecologically responsible):

· Legumes, tofu, tempeh, edamame, mycoprotein, quinoa, hemp seeds, spirulina, chlorella.

· No requirement for animal protein for optimal female endocrine function. Plant-based diets are associated with lower risk of ovulatory infertility.

· Soy and fertility: Soy isoflavones do not impair fertility; may slightly lengthen menstrual cycle (a marker of improved ovulatory function). Safe in iodine-sufficient populations.

Specific considerations:

· PCOS: Low glycaemic load, high fibre, anti-inflammatory diet. Weight loss is most potent intervention. Inositol supplementation may be considered adjunctive.

· Endometriosis: Anti-inflammatory diet; reduce red meat, increase omega-3s, vegetables, fruits. Some evidence for gluten-free diet in subset with gluten sensitivity; not routine.

· Uterine fibroids: Limited dietary evidence; some studies suggest reduced risk with green vegetables, fruit, vitamin D; increased risk with red meat, alcohol, hypertension.

· Menopause: Plant-forward diet supports bone health, cardiovascular health, weight maintenance. Phytoestrogen-rich foods (soy, flaxseed, legumes) may modestly reduce hot flushes; not harmful in women without oestrogen-sensitive malignancy.

Note on substances with addiction potential:

This guide does not recommend tea, coffee, alcohol, or tobacco in any form. Alcohol directly suppresses gonadotropin pulsatility, impairs ovulation, and is a risk factor for breast cancer. Caffeine is associated with delayed conception and increased miscarriage risk at high intakes, exacerbates anxiety and insomnia, and carries addiction potential. Tobacco is anti-oestrogenic, accelerates ovarian ageing, and is causally linked to infertility, ectopic pregnancy, and earlier menopause. No addictive substance is necessary for the optimisation of female endocrine health. Safe, non‑addictive lifestyle measures—particularly adequate nutrition, healthy body weight, regular moderate exercise, and stress reduction—are both safer and more foundational for long‑term reproductive and metabolic health.

---

6. How soon can one expect improvement and the ideal time frame to retest

Hypothalamic amenorrhoea / functional suppression:

· Oestradiol rise: 4–12 weeks after caloric repletion, exercise reduction, stress management.

· Ovulation resumption: 3–6 months; may take longer if prolonged suppression.

· Retest: After 3 months of lifestyle intervention; if no response, consider low-dose transdermal oestradiol for bone health.

PCOS – lifestyle intervention:

· Menstrual cyclicity: 2–3 months after 5% weight loss.

· Androgen reduction: 3–6 months.

· Retest: Testosterone, SHBG, fasting glucose/lipids at 6 months.

PCOS – pharmacotherapy:

· Oral contraceptives: Androgen suppression within 1–2 cycles; SHBG rises 2–3 months.

· Letrozole for ovulation: Ovulation occurs in cycle of administration (days 14–16).

· Retest: No routine hormonal monitoring; ultrasound for follicular tracking.

Primary ovarian insufficiency – hormone therapy:

· Symptom relief (hot flushes, vaginal dryness): 2–4 weeks.

· Bone protection: Years; monitor BMD every 1–2 years.

· Retest: TSH, prolactin, free testosterone (if symptoms of hypoandrogenism) not routinely indicated.

Hyperprolactinaemia – dopamine agonist:

· Prolactin normalisation: Days to weeks (cabergoline faster than bromocriptine).

· Tumour shrinkage: Weeks to months.

· Menses resumption: 4–12 weeks after prolactin normalisation.

· Retest: Prolactin at 4 weeks after initiation or dose change; once stable, every 6–12 months. MRI at 1 year for microadenoma; 3 months for macroadenoma.

Diminished ovarian reserve:

· No intervention increases AMH or improves oocyte quality. Do not retest AMH for monitoring; it declines inexorably.

· Retest: FSH, estradiol (day 2–4) annually if pursuing fertility; otherwise not indicated.

Luteal phase defect – progesterone supplementation:

· Ovulation induction cycles: Supplement from 3 days post-ovulation; progesterone level not routinely monitored.

· Natural conception: Mid-luteal progesterone >10 ng/mL on supplementation; adjust dose if low.

Retesting intervals (stable, treated):

· PCOS on OCP or metformin, stable: Annual metabolic panel (fasting glucose, lipids), blood pressure. No routine hormone retesting.

· Primary ovarian insufficiency on hormone therapy: Annual TSH (autoimmune), blood pressure; bone density every 1–2 years.

· Prolactinoma on dopamine agonist, stable: Prolactin every 6–12 months; MRI every 2–3 years (micro), annually initially (macro).

· Hypothalamic amenorrhoea, recovered: Once menses regular, no further testing unless recurrence.

· Perimenopause monitoring: FSH, estradiol only if clinically indicated; not required to confirm menopause (12 months amenorrhoea + age >50 sufficient).

---

Conclusion

The female hormone panel is the most context-dependent, time-sensitive, and physiologically nuanced of all endocrine assessments. It does not yield a single diagnostic number; it yields a pattern anchored to cycle day, energy balance, stress, and age.

A low FSH with low estradiol is not the same disease as a high FSH with low estradiol. An LH:FSH ratio of 3:1 on day 3 is not diagnostic of PCOS in the absence of hyperandrogenism. A low AMH at age 35 is not pathology—it is chronology. A mildly elevated prolactin is not a prolactinoma—it is often stress, sleep deprivation, or SSRIs.

The panel does not diagnose; it orients. It orients toward hypothalamus, pituitary, ovary, or adrenal. It distinguishes anovulation from ovarian failure, androgen excess from androgen deficiency, benign variants from treatable endocrinopathies.

The holistic management of an abnormal female hormone panel is therefore diagnostic precision first, aetiology-specific therapy second, and supportive, ecologically sustainable lifestyle interventions always. Hormone therapy (oestrogen, progesterone, combined oral contraceptives) is life‑changing for millions of women—not to be feared, but not to be prescribed empirically without a clear diagnostic hypothesis. Dopamine agonists restore fertility and prevent blindness. Letrozole and metformin offer evidence‑based ovulation induction. Inositol and vitamin D are adjuncts—not alternatives.

No addictive substance—whether caffeine, alcohol, or nicotine—is required for the optimisation of female reproductive endocrinology. Safe, non‑addictive, ecologically responsible dietary and lifestyle interventions are always preferred.

As with all blood tests, the female hormone panel is a conversation between the hypothalamus, the pituitary, the ovary, the calendar, and the clinician. Respect the cycle. Interpret the pattern. Treat the patient—not the number.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

Special note on protein in female endocrine health:

Plant‑based protein sources are nutritionally adequate for all women across the lifespan, including those with PCOS, primary ovarian insufficiency, endometriosis, and menopausal women. Soy, legumes, mycoprotein, and algae provide complete or complementary amino acid profiles. Concerns about soy isoflavones and fertility or hormone-sensitive conditions are largely unfounded in iodine-sufficient, euthyroid women consuming whole soy foods; isoflavone supplements are not recommended. Meat and fish are neither necessary nor preferred.

Special note on addictive substances:

This guide does not recommend tea, coffee, alcohol, or tobacco in any form. Alcohol directly suppresses gonadotropin pulsatility, impairs ovulation, is a risk factor for breast cancer, and carries addiction potential. Caffeine is associated with delayed conception and increased miscarriage risk at high intakes, exacerbates anxiety and insomnia, and has no established health benefit that outweighs its risks. Tobacco is anti-oestrogenic, accelerates ovarian ageing, and is causally linked to infertility, ectopic pregnancy, and earlier menopause. Safe, non‑addictive lifestyle interventions—particularly adequate nutrition, maintenance of healthy body weight, regular moderate physical activity, and stress reduction—are both safer and more foundational for long‑term female endocrine health. No addictive substance is necessary for the prevention or management of reproductive endocrine disorders.

---x-x---